Chronic Kidney Disease

A single patient with non-diabetic proteinuric CKD, declining steadily for over a year, sits at an eGFR the pivotal SGLT2-inhibitor trials only barely reached. The disagreement is whether today is still early enough to start the drug, or whether her numbers have already moved past the point where starting helps more than it alarms.

Two patients closing in on end-stage kidney disease test the same old instinct — that a RAAS inhibitor should come off before the kidneys 'take the hit' of dialysis planning. Recent trial evidence reverses that instinct in general. Whether it resolves either patient's own case is a separate question.

A proteinuric CKD patient's potassium has crept into dangerous territory on a proven, high-dose ACE inhibitor. The question isn't whether the hyperkalemia is real — it is — it's whether the right response is a second drug to manage it, or a smaller dose of the first one.

A diabetic CKD patient's proteinuria has plateaued despite both foundational drug classes already on board. A third RAAS-axis agent could push it lower — the argument is which one, or whether stacking a third agent on two already at work is worth what it costs in hyperkalemia risk.

A CKD patient's serum bicarbonate has drifted into mild acidosis. Whether treating that number actually slows her disease, or only treats a downstream marker of how far the disease has already gone, is a question the guidelines themselves decline to fully answer.

A CKD patient with disabling anemia remembers feeling far better years ago at a hemoglobin target current guidance no longer allows. Her own history of a heart attack sits her inside the exact population where correcting that high produced real harm in trial data.

A non-dialysis CKD patient wants an oral alternative to regular injections he has real trouble reaching. Two drugs in the same new class answered the cardiovascular-safety question that matters most here — and answered it differently.

A man beginning hemodialysis with an LDL of 165 has never taken a statin. The general case for treating that number runs straight into two trials that tested starting the same drug class in patients already on dialysis, and found it didn't do what it does everywhere else.

A referring physician wants to add allopurinol for a progressing CKD patient's elevated uric acid, reasoning from a mechanism that once looked plausible. Two negative trials since then already asked this exact question directly.

A dialysis patient's new atrial fibrillation raises a stroke-prevention question the pivotal DOAC trials were never designed to answer — most excluded this level of kidney failure outright, leaving the actual choice, and whether to anticoagulate at all, built on thinner evidence than the guideline language alone suggests.

A woman with mild-moderate CKD wants real relief from an osteoarthritis flare before surgery three months out. The instinct to withhold any NSAID from any CKD patient runs into the actual variable that changes her risk — and it isn't her CKD stage alone.

A diabetic CKD patient's eGFR keeps falling despite two proven kidney-protective drugs already at work. A third could help, per genuinely new trial evidence — but her blood sugar is already at goal, and the drug she'd be adding is one she's already said she's reluctant to take.

A covering physician wants to stop a well-tolerated, fifteen-year metformin regimen the moment eGFR crosses a threshold from training that predates the drug's own 2016 label revision. The patient's actual risk sits at a different number than the one that's driving the decision.

A hip-fracture patient with advanced CKD grew unexpectedly somnolent on a morphine PCA that had been working well. The problem isn't the dose she's receiving now — it's the active metabolite her kidneys can no longer clear, still accumulating from every dose already given.

A dialysis patient's rising ESA requirement raises a strategy question bigger than her own chart — whether the whole unit should dose iron on a schedule rather than only when levels fall low, and whether a safety signal buried inside one trial's composite endpoint deserves more individual scrutiny than the trial itself gave it.

A woman's CKD keeps progressing without a clear driver, while she's taken the same reflux medication for fifteen years. Newer analysis has reopened whether that medication is a real, modifiable contributor — but no trial has tested stopping it to find out.

SPRINT's CKD subgroup showed real benefit from a lower blood pressure target without accelerating kidney disease. Whether that population-level reassurance should decide the target for a specific, otherwise-fit man with one real fall already on his record is a narrower question than the trial answered.

With the decision against dialysis already made and settled, the question left is a narrower one: how to actually treat disabling itch in a woman whose kidneys can no longer clear the drug with the best evidence for treating it.